Literature DB >> 25265271

Effect of ghrelin on autonomic activity in healthy volunteers.

Takeshi Soeki1, Kunihiko Koshiba2, Toshiyuki Niki3, Kenya Kusunose4, Koji Yamaguchi4, Hirotsugu Yamada4, Tetsuzo Wakatsuki4, Michio Shimabukuro5, Kazuo Minakuchi6, Ichiro Kishimoto7, Kenji Kangawa7, Masataka Sata4.   

Abstract

Ghrelin is a novel growth hormone (GH)-releasing peptide originally isolated from the stomach. Recently, we have shown that ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. In the present study, we evaluated the effect of ghrelin on autonomic nerve activity in healthy human subjects. An intravenous bolus of human synthetic ghrelin (10μg/kg) was administered to 10 healthy men (mean age, 33 years). Holter monitoring assessment was performed before and during 2h after the ghrelin therapy. The standard deviation of normal RR intervals (SDNN), square root of the mean of the sum of the squares of differences between adjacent RR intervals (rMSSD), high-frequency power (HF), and low-frequency power (LF) were analyzed. Blood samples were also obtained before and after the therapy. A single administration of ghrelin decreased both heart rate and blood pressure. Interestingly, ghrelin significantly decreased the LF and LF/HF ratio of heart rate variability and increased the SDNN, rMSSD, and HF. Ghrelin also elicited a marked increase in circulating GH, but not insulin-like growth factor-1. These data suggest that ghrelin might suppress cardiac sympathetic nerve activity and stimulate cardiac parasympathetic nerve activity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autonomic nerve activity; Electrocardiography; Ghrelin; Heart rate variability; Hemodynamics

Mesh:

Substances:

Year:  2014        PMID: 25265271     DOI: 10.1016/j.peptides.2014.09.015

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

2.  Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.

Authors:  William S Denney; Gabriele E Sonnenberg; Santos Carvajal-Gonzalez; Theresa Tuthill; V Margaret Jackson
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

3.  Acute administration of acyl, but not desacyl ghrelin, decreases blood pressure in healthy humans.

Authors:  Cecilia J Zhang; Martin Bidlingmaier; Mekibib Altaye; Laura C Page; David D'Alessio; Matthias H Tschöp; Jenny Tong
Journal:  Eur J Endocrinol       Date:  2016-11-09       Impact factor: 6.664

Review 4.  Physiological significance of ghrelin in the cardiovascular system.

Authors:  Takeshi Tokudome; Kenji Kangawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2019       Impact factor: 3.493

Review 5.  Research progress of ghrelin on cardiovascular disease.

Authors:  Ming-Jie Yuan; Wei Li; Peng Zhong
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

Review 6.  Heal the heart through gut (hormone) ghrelin: a potential player to combat heart failure.

Authors:  Shreyasi Gupta; Arkadeep Mitra
Journal:  Heart Fail Rev       Date:  2020-10-06       Impact factor: 4.214

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.